
LH Stock Forecast & Price Target
LH Analyst Ratings
Bulls say
Labcorp Holdings demonstrates strong financial performance, evidenced by a 7.5% revenue increase in its Central Lab segment, primarily driven by significant trial wins and the introduction of advanced digital pathology and AI solutions. Additionally, the Diagnostic segment recorded solid revenue growth of 8.9% year-over-year, supported by both organic growth and acquisitions contributing equally to this increase. Furthermore, the company showcases robust operational metrics with a backlog of $8.71 billion, reflecting a 10% year-over-year improvement and a net book-to-bill ratio of 1.11x, indicating positive momentum and demand for its services.
Bears say
The financial outlook for Labcorp Holdings is negatively influenced by several key risks, including adverse shifts in reimbursement policies under the Protecting Access to Medicare Act (PAMA) and challenges related to the integration of acquisitions. Additionally, increased competition and economic uncertainty further exacerbate the company's financial stability, potentially impacting revenue growth. Although total requisitions showed a modest increase of 4.9%, this figure fell short of the anticipated growth of 5.2%, highlighting potential weaknesses in organic volume performance and overall market positioning.
This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
LH Analyst Forecast & Price Prediction
Start investing in LH
Order type
Buy in
Order amount
Est. shares
0 shares